SEC Form 4 · accession 0001209191-16-137799
Cascadian Therapeutics, Inc. · CASC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Dunseth Myers
Officer — President and CEO · Director
Period of report
Aug 17, 2016
Accepted (ET)
Aug 18, 2016 · 5:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001412067
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 17, 2016 | P | 45,000 | $1.1499 | A | 107,500 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported price in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $1.14 to $1.15 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.